Cell surface death receptor signaling in normal and cancer cells

Seminars in Cancer Biology

Volumn 13, Issue 2, 2003, Pages 135-147

  Özören, Nesrin ^a   El Deiry, Wafik S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Death receptor mutations; Death receptors; Extrinsic pathway; Intrinsic pathway; TRAIL cancer therapy

Indexed keywords

DNA; FAS ANTIGEN; FAS LIGAND; RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

CANCER CELL; CANCER THERAPY; CELL DEATH; CELL SURFACE; CHEMOTHERAPY; DNA DAMAGE; MEMBRANE POTENTIAL; MITOCHONDRION; MUTATION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TOXICITY;

EID: 0037376788     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044-579X(02)00131-1     Document Type: Article

References (144)

1. Kluck R.M., Martin S.J., Hoffman B.M., Zhou J.S., Green D.R., Newmeyer D.D. Cytochrome c activation of CPP32-like proteolysis plays a critical role in a Xenopus cell-free apoptosis system. EMBO J. 16:1997;4639-4649.
2. Kroemer G., Reed J.C. Mitochondrial control of cell death. Nat. Med. 6:2000;513-519.
3. Green D.R., Reed J.C. Mitochondria and apoptosis. Science. 281:1998;1309-1312.
4. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S.et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 91:1997;479-489.
5. Hengartner M.O. The biochemistry of apoptosis. Nature. 407:2000;770-776.
6. Du C., Fang M., Li Y., Li L., Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 102:2000;33-42.
7. Verhagen A.M., Ekert P.G., Pakusch M., Silke J., Connolly L.M., Reid G.E.et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell. 102:2000;43-53.
8. Daugas E., Susin S.A., Zamzami N., Ferri K.F., Irinopoulou T., Larochette N.et al. Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis. FASEB J. 14:2000;729-739.
9. Susin S.A., Lorenzo H.K., Zamzami N., Marzo I., Brenner C., Larochette N.et al. Mitochondrial release of caspase-2 and -9 during the apoptotic process. J. Exp. Med. 189:1999;381-394.
10. Suzuki Y., Imai Y., Nakayama H., Takahashi K., Takio K., Takahashi R. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol. Cell. 8:2001;613-621.
11. Parrish J., Li L., Klotz K., Ledwich D., Wang X., Xue D. Mitochondrial endonuclease G is important for apoptosis in C. elegans. Nature. 412:2001;90-94.
12. Li L.Y., Luo X., Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature. 412:2001;95-99.
13. El-Deiry W.S. The p53 pathway and cancer therapy. Cancer J. 11(5):1998;229-236.
14. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 80:1995;293-299.
15. Knudson C.M., Tung K.S., Tourtellotte W.G., Brown G.A., Korsmeyer S.J. Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science. 270:1995;96-99.
16. Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., Yamashita T.et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 288:2000;1053-1058.
17. Polyak K., Xia Y., Zweier J.L., Kinzler K.W., Vogelstein B. A model for p53-induced apoptosis. Nature. 389:1997;300-305. [see comments].
18. Attardi L.D., Reczek E.E., Cosmas C., Demicco E.G., McCurrach M.E., Lowe S.W.et al. PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. Genes Dev. 14:2000;704-718.
19. Buckbinder L., Talbott R., Velasco-Miguel S., Takenaka I., Faha B., Seizinger B.R.et al. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature. 377:1995;646-649.
20. Rich T., Allen R.L., Wyllie A.H. Defying death after DNA damage. Nature. 407:2000;777-783.
21. Soengas M.S., Alarcon R.M., Yoshida H., Giaccia A.J., Hakem R., Mak T.W.et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science. 284:1999;156-159.
22. Owen-Schaub L.B., Zhang W., Cusack J.C., Angelo L.S., Santee S.M., Fujiwara T.et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell Biol. 15:1995;3032-3040.
23. Wu G.S., Kim K., El-Deiry W.S. Killer/DR5, a novel DNA-damage inducible death receptor gene, links the p53-tumor suppressor to caspase activation and apoptotic death. Adv. Exp. Med. Biol. 465:2000;143-151. [in process citation].
24. Gross A., Yin X.M., Wang K., Wei M.C., Jockel J., Milliman C.et al. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J. Biol. Chem. 274:1999;1156-1163.
25. Muller M., Wilder S., Bannasch D., Israeli D., Lehlbach K., Li-Weber M.et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 188:1998;2033-2045.
26. Takimoto R., El-Deiry W.S. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site. Oncogene. 19:2000;1735-1743.
27. Burns T.F., Bernhard E.J., El-Deiry W.S. Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo. Oncogene. 20:2001;4601-4612.
28. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 104:2001;487-501.
29. Hu S., Yang X. dFADD, a novel death domain-containing adapter protein for the Drosophila caspase DREDD. J. Biol. Chem. 275:2000;30761-30764.
30. Beg A.A., Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 274:1996;782-784. [see comments].
31. Van Antwerp D.J., Martin S.J., Kafri T., Green D.R., Verma I.M. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science. 274:1996;787-789. [see comments].
32. Hsu H., Xiong J., Goeddel D.V. The TNF receptor 1-associated protein TRADD signals cell death and NF- kappa B activation. Cell. 81:1995;495-504.
33. Chinnaiyan A.M., O'Rourke K., Tewari M., Dixit V.M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell. 81:1995;505-512.
34. Liu Z.G., Hsu H., Goeddel D.V., Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell. 87:1996;565-576.
35. Kelliher M.A., Grimm S., Ishida Y., Kuo F., Stanger B.Z., Leder P. The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity. 8:1998;297-303.
36. Yeh W.C., Shahinian A., Speiser D., Kraunus J., Billia F., Wakeham A.et al. Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity. 7:1997;715-725.
37. Tartaglia L.A., Goeddel D.V. Two TNF receptors. Immunol. Today. 13:1992;151-153.
38. Schulze-Osthoff K., Ferrari D., Los M., Wesselborg S., Peter M.E. Apoptosis signaling by death receptors. Eur. J. Biochem. 254:1998;439-459.
39. Nagata S. Apoptosis by death factor. Cell. 88:1997;355-365.
40. Korner H., Cook M., Riminton D.S., Lemckert F.A., Hoek R.M., Ledermann B.et al. Distinct roles for lymphotoxin-alpha and tumor necrosis factor in organogenesis and spatial organization of lymphoid tissue. Eur. J. Immunol. 27:1997;2600-2609.
41. Pfeffer K., Matsuyama T., Kundig T.M., Wakeham A., Kishihara K., Shahinian A.et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell. 73:1993;457-467.
42. Erickson S.L., de Sauvage F.J., Kikly K., Carver-Moore K., Pitts-Meek S., Gillett N.et al. Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature. 372:1994;560-563.
43. Ashkenazi A., Dixit V.M. Death receptors: signaling and modulation. Science. 281:1998;1305-1308.
44. Nagata S. Fas ligand-induced apoptosis. Annu. Rev. Genet. 33:1999;29-55.
45. Nagata S., Golstein P. The Fas death factor. Science. 267:1995;1449-1456.
46. Zhou Z., Hartwieg E., Horvitz H.R. CED-1 is a transmembrane receptor that mediates cell corpse engulfment in C. elegans. Cell. 104:2001;43-56.
47. Pitti R.M., Marsters S.A., Lawrence D.A., Roy M., Kischkel F.C., Dowd P.et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 396:1998;699-703.
48. Liu Q.A., Hengartner M.O. Candidate adaptor protein CED-6 promotes the engulfment of apoptotic cells in C. elegans. Cell. 93:1998;961-972.
49. Gumienny T.L., Brugnera E., Tosello-Trampont A.C., Kinchen J.M., Haney L.B., Nishiwaki K.et al. Ced-12/elmo, a novel member of the crkii/dock180/rac pathway, is required for phagocytosis and cell migration. Cell. 107:2001;27-41.
50. Zhou L., Schnitzler A., Agapite J., Schwartz L.M., Steller H., Nambu J.R. Cooperative functions of the reaper and head involution defective genes in the programmed cell death of Drosophila central nervous system midline cells. Proc. Natl. Acad. Sci. U.S.A. 94:1997;5131-5136.
51. Hengartner M.O., Horvitz H.R. C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2. Cell. 76:1994;665-676.
52. Brodsky M.H., Nordstrom W., Tsang G., Kwan E., Rubin G.M., Abrams J.M. Drosophila p53 binds a damage response element at the reaper locus. Cell. 101:2000;103-113.
53. Zha J., Weiler S., Oh K.J., Wei M.C., Korsmeyer S.J. Posttranslational N-myristoylation of BID as a molecular switch for targeting mitochondria and apoptosis. Science. 290:2000;1761-1765.
54. Walczak H., Krammer P.H. The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. Exp. Cell Res. 256:2000;58-66.
55. Jenkins M., Keir M., McCune J.M. A membrane-bound Fas decoy receptor expressed by human thymocytes. J. Biol. Chem. 275:2000;7988-7993.
56. Vercammen D., Brouckaert G., Denecker G., Van de C.M., Declercq W., Fiers W.et al. Dual signaling of the Fas receptor: initiation of both apoptotic and necrotic cell death pathways. J. Exp. Med. 188:1998;919-930.
57. Matsumura H., Shimizu Y., Ohsawa Y., Kawahara A., Uchiyama Y., Nagata S. Necrotic death pathway in Fas receptor signaling. J. Cell Biol. 151:2000;1247-1256.
58. Vercammen D., Beyaert R., Denecker G., Goossens V., Van Loo G., Declercq W.et al. Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J. Exp. Med. 187:1998;1477-1485.
59. Watanabe-Fukunaga R., Brannan C.I., Copeland N.G., Jenkins N.A., Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 356:1992;314-317.
60. Takahashi T., Tanaka M., Brannan C.I., Jenkins N.A., Copeland N.G., Suda T.et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 76:1994;969-976.
61. Krammer P.H. CD95's deadly mission in the immune system. Nature. 407:2000;789-795.
62. Ogasawara J., Watanabe-Fukunaga R., Adachi M., Matsuzawa A., Kasugai T., Kitamura Y.et al. Lethal effect of the anti-Fas antibody in mice. Nature. 364:1993;806-809.
63. Wiley S.R., Schooley K.A., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K.et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:1995;673-682.
64. Mongkolsapaya J., Grimes J.M., Chen N., Xu X.N., Stuart D.I., Jones E.Y.et al. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat. Struct. Biol. 6:1999;1048-1053.
65. Kayagaki N., Yamaguchi N., Nakayama M., Eto H., Okumura K., Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189:1999;1451-1460.
66. Fanger N.A., Maliszewski C.R., Schooley K., Griffith T.S. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Exp. Med. 190:1999;1155-1164.
67. Griffith T.S., Wiley S.R., Kubin M.Z., Sedger L.M., Maliszewski C.R., Fanger N.A. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J. Exp. Med. 189:1999;1343-1354.
68. Kayagaki N., Yamaguchi N., Nakayama M., Takeda K., Akiba H., Tsutsui H.et al. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J. Immunol. 163:1999;1906-1913.
69. Smyth M.J., Cretney E., Takeda K., Wiltrout R.H., Sedger L.M., Kayagaki N.et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J. Exp. Med. 193:2001;661-670.
70. Pan G., O'Rourke K., Chinnaiyan A.M., Gentz R., Ebner R., Ni J.et al. The receptor for the cytotoxic ligand TRAIL. Science. 276:1997;111-113.
71. Walczak H., Degli-Esposti M.A., Johnson R.S., Smolak P.J., Waugh J.Y., Boiani N.et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16:1997;5386-5397.
72. Screaton G.R., Mongkolsapaya J., Xu X.N., Cowper A.E., McMichael A.J., Bell J.I. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr. Biol. 7:1997;693-696.
73. Pan G., Ni J., Wei Y.F., Yu G., Gentz R., Dixit V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 277:1997;815-818. [see comments].
74. Sheridan J.P., Marsters S.A., Pitti R.M., Gurney A., Skubatch M., Baldwin D.et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 277:1997;818-821.
75. Wu G.S., Burns T.F., McDonald E.R., Jiang W., Meng R., Krantz I.D.et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 17:1997;141-143.
76. MacFarlane M., Ahmad M., Srinivasula S.M., Fernandes-Alnemri T., Cohen G.M., Alnemri E.S. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J. Biol. Chem. 272:1997;25417-25420.
77. Chaudhary P.M., Eby M., Jasmin A., Bookwalter A., Murray J., Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity. 7:1997;821-830.
78. Sprick M.R., Weigand M.A., Reiser E., Rauch C.T., Juo P., Blenis J.et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity. 12:2000;599-609.
79. Kischkel F.C., Lawrence D.A., Chuntharapai A., Schow P., Kim K.J., Ashkenazi A. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity. 12:2000;611-620.
80. Kischkel F.C., Lawrence D.A., Tinel A., LeBlanc H., Virmani A., Schow P.et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J. Biol. Chem. 276:2001;46639-46646.
81. Wang J., Chun H.J., Wong W., Spencer D.M., Lenardo M.J. Caspase-10 is an initiator caspase in death receptor signaling. Proc. Natl. Acad. Sci. U.S.A. 98:2001;13884-13888.
82. Yamada H., Tada-Oikawa S., Uchida A., Kawanishi S. TRAIL causes cleavage of bid by caspase-8 and loss of mitochondrial membrane potential resulting in apoptosis in BJAB cells. Biochem. Biophys. Res. Commun. 265:1999;130-133.
83. Degli-Esposti M.A., Smolak P.J., Walczak H., Waugh J., Huang C.P., DuBose R.F.et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. 186:1997;1165-1170.
84. Degli-Esposti M.A., Dougall W.C., Smolak P.J., Waugh J.Y., Smith C.A., Goodwin R.G. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 7:1997;813-820.
85. Truneh A., Sharma S., Silverman C., Khandekar S., Reddy M.P., Deen K.C.et al. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J. Biol. Chem. 275:2000;23319-23325.
86. Schneider P., Thome M., Burns K., Bodmer J.L., Hofmann K., Kataoka T.et al. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity. 7:1997;831-836.
87. Marsters S.A., Sheridan J.P., Pitti R.M., Huang A., Skubatch M., Baldwin D.et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7:1997;1003-1006.
88. Long Q., Huang H., Shafizadeh E., Liu N., Lin S. Stimulation of erythropoiesis by inhibiting a new hematopoietic death receptor in transgenic zebrafish. Nat. Cell Biol. 2:2000;549-552.
89. Wu G.S., Burns T.F., Zhan Y., Alnemri E.S., El-Deiry W.S. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res. 59:1999;2770-2775.
90. Pan G., Ni J., Yu G., Wei Y.F., Dixit V.M. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett. 424:1998;41-45.
91. Nicholson D.W. From bench to clinic with apoptosis-based therapeutic agents. Nature. 407:2000;810-816.
92. Kim K., Fisher M.J., Xu S.Q., El-Deiry W.S. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res. 6:2000;335-346.
93. Rieger J., Naumann U., Glaser T., Ashkenazi A., Weller M. APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett. 427:1998;124-128.
94. Zhang X.D., Franco A., Myers K., Gray C., Nguyen T., Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res. 59:1999;2747-2753.
95. Mitsiades N., Poulaki V., Mitsiades C., Tsokos M. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Cancer Res. 61:2001;2704-2712.
96. Griffith T.S., Chin W.A., Jackson G.C., Lynch D.H., Kubin M.Z. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 161:1998;2833-2840.
97. Zhang X.D., Zhang X.Y., Gray C.P., Nguyen T., Hersey P. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res. 61:2001;7339-7348.
98. Chen X., Thakkar H., Tyan F., Gim S., Robinson H., Lee C.et al. Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene. 20:2001;6073-6083.
99. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M.et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5:1999;157-163. [see comments].
100. Nagane M., Pan G., Weddle J.J., Dixit V.M., Cavenee W.K., Huang H.J. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res. 60:2000;847-853.
101. Kim K., Takimoto R., Dicker D.T., Chen Y., Gazitt Y., El-Deiry W.S. Enhanced TRAIL sensitivity by p53 overexpression in human cancer but not normal cell lines. Int. J. Oncol. 18:2001;241-247.
102. Chinnaiyan A.M., Prasad U., Shankar S., Hamstra D.A., Shanaiah M., Chenevert T.L.et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 97:2000;1754-1759.
103. Takeda K., Hayakawa Y., Smyth M.J., Kayagaki N., Yamaguchi N., Kakuta S.et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat. Med. 7:2001;94-100.
104. Zamai L., Ahmad M., Bennett I.M., Azzoni L., Alnemri E.S., Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J. Exp. Med. 188:1998;2375-2380.
105. Thomas W.D., Hersey P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J. Immunol. 161:1998;2195-2200.
106. Liu S., Yu Y., Zhang M., Wang W., Cao X. The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells. J. Immunol. 166:2001;5407-5415.
107. Hsu H., Shu H.B., Pan M.G., Goeddel D.V. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 84:1996;299-308.
108. Thome M., Schneider P., Hofmann K., Fickenscher H., Meinl E., Neipel F.et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature. 386:1997;517-521.
109. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V.et al. Inhibition of death receptor signals by cellular FLIP. Nature. 388:1997;190-195. [see comments].
110. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 281:1998;1322-1326.
111. Wei M.C., Zong W.X., Cheng E.H., Lindsten T., Panoutsakopoulou V., Ross A.J.et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 292:2001;727-730.
112. Deveraux Q.L., Reed J.C. IAP family proteins - suppressors of apoptosis. Genes Dev. 13:1999;239-252.
113. Roy N., Deveraux Q.L., Takahashi R., Salvesen G.S., Reed J.C. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 16:1997;6914-6925.
114. Bratton S.B., Walker G., Srinivasula S.M., Sun X.M., Butterworth M., Alnemri E.S.et al. Recruitment, activation and retention of caspases-9 and -3 by Apaf-1 apoptosome and associated XIAP complexes. EMBO J. 20:2001;998-1009.
115. Srinivasula S.M., Hegde R., Saleh A., Datta P., Shiozaki E., Chai J.et al. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature. 410:2001;112-116.
116. Beere H.M., Wolf B.B., Cain K., Mosser D.D., Mahboubi A., Kuwana T.et al. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat. Cell Biol. 2:2000;469-475.
117. Saleh A., Srinivasula S.M., Balkir L., Robbins P.D., Alnemri E.S. Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat. Cell Biol. 2:2000;476-483.
118. Pandey P., Saleh A., Nakazawa A., Kumar S., Srinivasula S.M., Kumar V.et al. Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90a. EMBO J. 19:2000;4310-4322.
119. Bruey J.M., Ducasse C., Bonniaud P., Ravagnan L., Susin S.A., Diaz-Latoud C.et al. Hsp27 negatively regulates cell death by interacting with cytochrome c. Nat. Cell Biol. 2:2000;645-652.
120. Hahne M., Rimoldi D., Schroter M., Romero P., Schreier M., French L.E.et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science. 274:1996;1363-1366. [see comments].
121. Takakuwa T., Dong Z., Nakatsuka S., Kojya S., Harabuchi Y., Yang W.I.et al. Frequent mutations of Fas gene in nasal NK/T cell lymphoma. Oncogene. 21:2002;4702-4705.
122. Takayama H., Takakuwa T., Tsujimoto Y., Tani Y., Nonomura N., Okuyama A.et al. Frequent Fas gene mutations in testicular germ cell tumors. Am. J. Pathol. 161:2002;635-641.
123. Boldrini L., Faviana P., Gisfredi S., Di Quirico D., Lucchi M., Mussi A.et al. Identification of Fas (APO-1/CD95) and p53 gene mutations in non-small cell lung cancer. Int. J. Oncol. 20:2002;155-159.
124. Shin M.S., Park W.S., Kim S.Y., Kim H.S., Kang S.J., Song K.Y.et al. Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma. Am. J. Pathol. 154:1999;1785-1791.
125. Gronbaek K., Straten P.T., Ralfkiaer E., Ahrenkiel V., Andersen M.K., Hansen N.E.et al. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood. 92:1998;3018-3024.
126. Lee S.H., Shin M.S., Park W.S., Kim S.Y., Dong S.M., Pi J.H.et al. Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res. 59:1999;3068-3072.
127. Lee S.H., Shin M.S., Park W.S., Kim S.Y., Kim H.S., Han J.Y.et al. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene. 18:1999;3754-3760.
128. Ozoren N., Fisher M.J., Kim K., Liu C.X., Genin A., Shifman Y.et al. Homozygous deletion of the death receptor DR4 gene in a nasopharyngeal cancer cell line is associated with TRAIL resistance. Int. J. Oncol. 16:2000;917-925.
129. Fisher M.J., Virmani A.K., Wu L., Aplenc R., Harper J.C., Powell S.M.et al. Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin. Cancer Res. 7:2001;1688-1697.
130. Pai S.I., Wu G.S., Ozoren N., Wu L., Jen J., Sidransky D.et al. Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res. 58:1998;3513-3518.
131. Lee S.H., Shin M.S., Kim H.S., Lee H.K., Park W.S., Kim S.Y.et al. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res. 59:1999;5683-5686.
132. McDonald E.R. III, Chui P.C., Martelli P.F., Dicker D.T., El-Deiry W.S. Death domain mutagenesis of KILLER/DR5 reveals residues critical for apoptotic signaling. J. Biol. Chem. 276:2001;14939-14945.
133. Park W.S., Lee J.H., Shin M.S., Park J.Y., Kim H.S., Kim Y.S.et al. Inactivating mutations of KILLER/DR5 gene in gastric cancers. Gastroenterology. 121:2001;1219-1225.
134. Sheikh M.S., Huang Y., Fernandez-Salas E.A., El-Deiry W.S., Friess H., Amundson S.et al. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene. 18:1999;4153-4159.
135. van Noesel M.M., van Bezouw S., Salomons G.S., Voute P.A., Pieters R., Baylin S.B.et al. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation. Cancer Res. 62:2002;2157-2161.
136. Bullani R.R., Huard B., Viard-Leveugle I., Byers H.R., Irmler M., Saurat J.H.et al. Selective expression of FLIP in malignant melanocytic skin lesions. J. Invest. Dermatol. 117:2001;360-364.
137. Jo M., Kim T.H., Seol D.W., Esplen J.E., Dorko K., Billiar T.R.et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. 6:2000;564-567. [see comments].
138. Ozoren N., Kim K., Burns T.F., Dicker D.T., Moscioni A.D., El-Deiry W.S. The caspase 9 inhibitor Z-LEHD-FMK protects human liver cells while permitting death of cancer cells exposed to tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 60:2000;6259-6265.
139. Lawrence D., Shahrokh Z., Marsters S., Achilles K., Shih D., Mounho B.et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med. 7:2001;383-385.
140. L M., Glaccum M.B., Schuh J.C., Kanaly S.T., Williamson E., Kayagaki N.et al. Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur. J. Immunol. 32:2002;2246-2254.
141. Hyer M.L., Sudarshan S., Kim Y., Reed J.C., Dong J., Schwartz D.A.et al. Down-regulation of c-FLIP sensitizes D$145 prostate cancer cells to fas-mediated apoptosis. Cancer Biol. Ther. 1:2002;405-410.
142. Yang X. The FLIP side of cancer cell death. Cancer Biol. Ther. 1:2002;411-412.
143. Kelly M.M., Hoel B.D., Voelkel-Johnson C. Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with loss of c-FLIP expression. Cancer Biol. Ther. 1:2002;520-527.
144. Guo F., Bhalla K. The FLIP variation on the TRAIL DISC: doxorubicin conducts the swan song. Cancer Biol. Ther. 1:2002;528-529.